Targeting Epigenetic Causes of Ewing's Sarcoma with David Arthur Salarius Pharmaceuticals

Published: April 7, 2020, 2:38 p.m.

David Arthur, CEO, Salarius Pharmaceuticals explains the role of our epigenome and what happens when someone is suffering from an epigenetic illness such as Ewing's sarcoma.  A whole series of cancers can trace their cause back to the body misreading genes and that leads to dysregulation of genetic expression. With few options to treat Ewing's sarcoma, a rare orphan pediatric disease, Salarius is testing a new treatment that can provide hope to patients by inhibiting the LSD1 enzyme and effectively addressing the dysregulation.

@salariuspharma

#ewingsarcoma #ewingssarcoma #rarediseases

Salariuspharma.com

Download the transcript here

salarius